- Shares of Oxygen Biotherapeutics (OXBT -5%) are taking a breather today (perhaps we should call it a well-deserved rest) after running up over 300% in five sessions.
- Incidentally, MarketWatch has picked up on the recent rally, noting that OXBT "could have been considered a penny stock [last week] with shares trading under $2" before the levosimendan news helped the stock "more than quintuple."
- Meanwhile, shares of similarly-named OXiGENE (OXGN +74.4%) are staging a fantastic rally, on volume of 9.2M versus a 10-day average of just 55K. Here's SA contributor PropThink: "Now we're just walking backwards through the NASDAQ listings."
Oxygen Biotherapeutics takes a break, OXiGENE goes parabolic
From other sites
at CNBC.com (Jun 25, 2014)
at CNBC.com (Mar 31, 2014)
at CNBC.com (Mar 17, 2014)
at CNBC.com (Mar 4, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs